Non-small cell lung cancer (NSCLC) is the most common cancer, accounting for approximately 85% of the total lung cancers in the United States. Almost 500K cases in the 7MM were diagnosed in 2022 alone. Moreover, significant deaths were recorded at the end of the same year. Analysis indicates that the most common genetic alteration in Non-Small Cell Lung Cancer (NSCLC) is the EGFR mutation, which occurs in approximately 20–25% of patients. These mutations primarily involve exon 19, where a deletion occurs, and exon 21, specifically the L858R mutation. Together, these mutations account for about 80–85% of all EGFR mutations in NSCLC.
Non-small cell lung cancer is any...
